Sign in
EFTRW Stock Price, Chart, Stats & News
eFFECTOR Therapeutics, Inc.
Save
eFFECTOR Therapeutics, Inc. (EFTRW) does not currently pay a dividend.
2,822
Market cap
–
Current P/E
–
Forward P/E
EFTRW chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -174.31% |
ROE | 3771.56% |
D/E | -3.55x |
Interest coverage ratio | – |
EFTRW valuation
P/E | – |
P/S | – |
P/B | -0.00x |
P/CF | -0.00x |
P/FCF | -0.00x |
P/OCF | -0.00x |
PEG | -0.00x |
EV multiple | 0.17x |
About
eFFECTOR Therapeutics, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective translation regulator inhibitors aimed at combating cancer. Their primary investigational drug, Tomivosertib, is an orally administered small-molecule MNK inhibitor currently undergoing Phase 2b clinical trials. This candidate is being evaluated for its efficacy in patients suffering from metastatic non-small cell lung cancer.
Similar securities
Based on sector and market capitalization
Report issue